COO$72.49
$71.63
Chart
Performance
Key Stats
AI COO Summary
Powered by LiveAIAI Scoreboard
Powered by LiveAIOverall Analysis
BuyThe Cooper Companies shows strong fundamental performance driven by its healthcare segments, particularly in contact lenses and women's health. While valuation is somewhat elevated, consistent earnings growth and a solid balance sheet support a positive outlook. Technicals indicate a recent dip but long-term averages remain supportive.
Thematic
The Cooper Companies operates in stable, albeit growing, healthcare sectors. Trends in aging populations and personalized medicine provide a backdrop, but the company is less exposed to high-growth disruptive themes like AI compared to tech-centric firms.
Fundamental
The Cooper Companies demonstrates robust financial health with consistent revenue growth, improving profitability, and a manageable debt level. Its strong balance sheet and consistent earnings per share (EPS) growth highlight its operational efficiency and market position.
Technical
The stock is trading below its 52-week high and has shown recent price weakness. While key moving averages (50-day, 100-day, 200-day) are still generally supportive, momentum indicators suggest a cooling off from previous highs.
| Factor | Score |
|---|---|
| Healthcare Sector Growth | 80 |
| Innovation in Medical Devices | 75 |
| Digital Health Integration | 50 |
| Regulatory Landscape | 60 |
| Competitive Moat | 70 |
| Factor | Score |
|---|---|
| Valuation | 50 |
| Profitability | 75 |
| Growth | 70 |
| Balance Sheet Health | 80 |
| Cash Flow | 85 |
| Earnings Consistency | 90 |
| Factor | Score |
|---|---|
| Trend Analysis | 70 |
| Momentum | 60 |
| Volume Trends | 70 |
| Support & Resistance | 65 |
| Short-Term Indicators | 65 |
AI Investing Checklist
Powered by LiveAIBullish Points (7)
Consistent EPS Beats
The company has beaten earnings per share (EPS) estimates in 10 of the last 12 quarters, indicating strong operational execution and profitability management.
Undervalued P/E Ratio
The current Price-to-Earnings (P/E) ratio of 35.65 is below the industry average of 40, suggesting potential undervaluation relative to peers.
Bearish Points (7)
High Price-to-Sales Ratio
The trailing Price-to-Sales (P/S) ratio of 3.7, while improving from prior years, remains high, indicating that the market values each dollar of sales significantly.
Slowing Revenue Growth Trends
While the company has posted revenue growth, the annual revenue growth rate has shown a declining trend from 2021 to 2024, suggesting a maturing market or increased competition.
Calendar
July 2023
26
Ex-Dividend Date
August 2023
11
Next Dividend Date
August 2025
27
Next Earnings Date
H: $1.09
A: $1.06
L: $1.02
H: 1.07B
A: 1.06B
L: 1.05B
Profile
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia; and spherical lense, including lenses that correct near and farsightedness in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage to health care professionals and patients worldwide. It offers surgical and office products, including paragard contraceptive intrauterine devices; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Seasonals
Price Target
93.09 USD
The 39 analysts offering 1 year price forecasts for COO have a max estimate of 105.00 and a min estimate of 76.00.
Debt Level and Coverage
Financial Position Analysis
Ownership
Capital Structure
Valuation - Summary
Valuation - Ratios
Revenue to Profit Conversion
Balance Sheet
Income Statement
Cash Flow
Related Companies
Powered by LiveAIWeight: 98
Direct and strong competitor in the contact lens market and other eye care surgical products, similar to CooperVision.
Weight: 95
Large diversified healthcare conglomerate with Acuvue, a major direct competitor in the contact lens market.
Weight: 93
Strong direct competitor and complementary company specializing in women's health diagnostics and surgical products, aligning with CooperSurgical.
Weight: 90
Direct competitor in contact lenses (Bausch + Lomb) and other eye care pharmaceutical products.